



Formulary Update

Saskatchewan

Teva Canada is pleased to announce the following products have Exception Drug Status in Saskatchewan effective January 1, 2022.

Product Name	Strength	Size	Item Number	DIN
Octreotide for Injectable Suspension	10 mg	8mL, Vial	65409-0001	02503751
Octreotide for Injectable Suspension	20 mg	8mL, Vial	65410-0001	02503778
Octreotide for Injectable Suspension	30 mg	8mL, Vial	65411-0001	02503786